ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an exclusive educational event at IDWeek 2021 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Jolan Walter from the University of South Florida and Johns Hopkins All Children's Hospital. Two leading experts in the management of respiratory syncytial virus (RSV) and other respiratory viruses in immunocompromised patients will discuss today's key clinical challenges and emerging treatment strategies. A novel intravenous immunoglobulin (IVIG) product with a unique composition will be introduced, including patient cases.

ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a virtual fireside chat at the Cantor Healthcare Conference on September 30, 2021, at 9:20 a.m. ET.

ADMA Biologics to Virtually Participate in the Cantor Healthcare Conference

The FDA has approved ADMA Biologics Inc's (NASDAQ:ADMA) in-house aseptic fill-finish machine, the VanRx SA25. Related Content:   ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility.

ADMA Biologics' Aseptic Fill-Finish Machine Scores FDA Approval

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 12:30 p.m. ET.

ADMA Biologics to Virtually Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Last week, there were three significant developments with respect to ADMA. The market has taken these events to be bearish for ADMA's outlook, with the stock selling off this week.

ADMA Biologics: Recent Significant Developments And Their Implications For The Stock

The FDA has approved ADMA Biologics Inc's (NASDAQ:ADMA) BioCenters plasma collection facility in Maryville, Tennessee.  The plasma collection facility commenced operations and initiated source plasma collection in Q4 of 2020.

ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility

The shares of ADMA Biologics Inc (NASDAQ: ADMA) increased by over 15% pre-market. This is why it happened.

ADMA Biologics Shares Increase Over 15% Pre-Market: Why It Happened

RAMSEY, N.J. and BOCA RATON, Fla. and MARYVILLE, Tenn., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its ADMA BioCenters plasma collection facility located in Maryville, Tennessee. This plasma collection facility commenced operations and initiated source plasma collection in the fourth quarter of 2020. With today's approval, this facility is now FDA-licensed to collect and introduce into interstate commerce human source plasma for further manufacturing in the U.S.

ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN

ADMA reported their Q2 earnings that revealed a 129% increase year-over-year in revenues. In addition, the company reduced their net loss, while improving gross margins.

ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2021 Results - Earnings Call Transcript

Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Quarter 2020

ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments

RAMSEY, N.J. and BOCA RATON, Fla. and CONYERS, Ga., Aug. 10, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters plasma collection facility located in Conyers, Georgia. In conjunction with the plasma collection center opening, ADMA also announced the implementation of the Haemonetics' Persona® Plasma Collection Solution for the NexSys PCS® system (“Persona”) across its plasma collection center network.

ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics' Persona Technology for NexSys Plasma Collection System

ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes

ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB®

Conference Call Scheduled for August 11, 2021 at 4:30 p.m. ET Conference Call Scheduled for August 11, 2021 at 4:30 p.m. ET

ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Adma Biologics (ADMA) Report Negative Q2 Earnings? What You Should Know

Canopy Growth

Hewlett Packard

Kirkland's

Zoom Video

Some of the stocks that may grab investor focus today are: Wall Street expects Hewlett Packard Enterprise Co (NYSE: HPE) to post quarterly earnings at $0.42 per share on revenue of $6.62 billion after the closing bell. Hewlett Packard Enterprise shares fell 2.3% to close at $15.96 on Friday.

5 Stocks To Watch For June 1, 2021

ADMA delivered another great quarter and is poised to experience revenue growth and margin expansion and has a path to profitability.

ADMA Biologics: Getting Unstuck Between A Rock And A Hard Place

ADMA Biologics Inc. (ADMA) CEO Adam Grossman on Q1 2021 Results - Earnings Call Transcript

Shares of ADMA Biologics (NASDAQ:ADMA) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 38.46% over the past year to ($0.16), which beat the estimate of ($0.17).

Recap: ADMA Biologics Q1 Earnings

Achieved First Quarter 2021 Total Revenues of $16.0 Million, a 57% Increase Over First Quarter 2020

ADMA Biologics Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress and Accomplishments

On Wednesday, May 12, ADMA Biologics (NASDAQ:ADMA) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

ADMA Biologics Earnings Preview

ADMA Biologics (ADMA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why ADMA Biologics (ADMA) Might Surprise This Earnings Season

Conference Call Scheduled for May 12, 2021 at 4:30 p.m. ET Conference Call Scheduled for May 12, 2021 at 4:30 p.m. ET

ADMA Biologics to Report First Quarter 2021 Financial Results on May 12, 2021

Today, ADMA stock is a big mover as the company announced a very bullish FDA approval allowing the company to scale its core product. The post ADMA Stock: The Big FDA News Boosting ADMA Biologics Today appeared first on InvestorPlace.

News for ADMA Biologics Stock (ADMA)